A Phase 3 interventional study of Raphamin and Placebo in Community-acquired Pneumonia and Pneumonia, sponsored by Materia Medica Holding. Completed at 38 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Community-Acquired Pneumonia with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Community-Acquired Pneumonia · Russian Federation.
Among the 14 studies in Community-Acquired Pneumonia with a site in Russian Federation, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 7 in phase 3, and was the 14th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.
Browse Community-Acquired Pneumonia studies →None of the 14 studies in Community-Acquired Pneumonia with a site in Russian Federation is open now. The open studies under Community-Acquired Pneumonia, anywhere →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2023.
This study's enrollment of 370 is above the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Median enrollment 356 across the 12 interventional studies, 1,456 across the 2 observational. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 10 most frequent:
Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Materia Medica Holding has 1 study filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Community-Acquired Pneumonia with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
Design: a multicenter, double-blind, placebo-controlled, randomized in parallel-group trial.
The study enrolls male and female outpatients aged 18 to 65 years with typical symptoms of community-acquired pneumonia (CAP): axillary body temperature ≥38.00C, acute cough, shortness of breath (dyspnea), chest pain when breathing, fatigue, night sweats. Symptoms are associated with previous upper respiratory tract infection or acute bronchitis. The investigator assesses a prognosis and determines where the patient will receive treatment using the CRB-65 score which includes estimation of Confusion, Respiratory rate, Blood pressure, and Age (≥ 65 years) (min "0", max "4" points; only estimation "0" points is indication for outpatient treatment).
At the first visit (day 1), after signing the patient information sheet and informed consent form for participation in a clinical trial, the investigator collects complaints and medical history, conducts a physical examination and assessment of vital signs, and measures capillary blood oxygen saturation (SpO2), records comorbidities and concomitant therapies, collects blood samples for laboratory tests, and orders a dual-view chest X-ray or chest CT scan. If X-ray/CT shows no changes in the lungs or changes that are not typical for pneumonia, the patient is not included in the clinical trial. The investigator determines a therapeutic approach in compliance with the current standards.
At the first visit (day 1), patients are randomized to one of two treatment groups: patients in Group 1 receive Amoxicillin + Clavulanic acid (Amoxiclav) and Rafamine for 7 days; patients in Group 2 take Amoxiclav and Placebo for 7 days. All patients are provided with the drug Amoxiclav. In addition, all patients are provided with the antipyretic drug Paracetamol and a classic mercury-free thermometer to measure axillary temperature.
A second visit (3/4 days) is carried out 48-72 hours after the start of treatment to assess the effectiveness and safety of the initial course of antibiotic therapy. The investigator collects complaints, performs physical examination, and evaluates the vital signs and SpO2 level. If there is no response to initial antibiotic therapy, the decision about the therapeutic approach is made by the investigator. If hospitalization occurs, the patient ends participation in the study because he or she has reached the study endpoint.
If antibiotic therapy is effective, it is continued for 7 days. After 7 days of treatment, a third visit is carried out (day 8), at which the researcher collects the patient's complaints, conducts a physical examination and assessment of vital signs, measures SpO2 and prescribes a clinical blood test. If the patient meets the criteria for sufficiency of antibiotic therapy, the investigator stops prescribing the antibiotic.
If a positive response to the first course of antibiotic therapy is achieved, the patient continues to participate in the study. The patient is observed for 7 days. On day 15±1, the fourth visit is carried out, during which the researcher collects the patient's complaints, conducts a physical examination and assesses vital signs, measures SpO2 and prescribes a follow-up X-ray/CT scan. The patient returns the study drug and the investigator performs a compliance calculation. In total, patients are observed for 15 days.
The study uses an electronic patient diary (EPD) to record axillary temperature daily in the morning and evening. All temperature measurements during the study should be made with the same thermometer. The patient should bring the thermometer used for measurements to the health center visit. In addition, the patient should also use the EPD to record symptoms, if any, time of administration of the antipyretic dose, and any worsening of his/her condition (if applicable) to assess safety and record adverse events.
The investigator teaches the patient how to complete the diary at Visit 1. The EPD is available for completion throughout the patient's participation in the study.
An unscheduled visit may be made during the study if the patient's condition worsens or at the discretion of the investigator.
If clinical cure is not achieved by 15±1 days, the patient ends participation in the study because he or she has reached the study endpoint. The researcher determines the approach to further observation and treatment of the patient in accordance with current recommendations.
Subjects are permitted to take medications for concomitant medical conditions during the study, with the exception of medications listed in the Prohibited Concomitant Treatments section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The diagnosis of community-acquired pneumonia presupposes that the patient has focal infiltration of the lung tissue, confirmed by imaging (X-ray/CT), and the presence of at least two clinical symptoms:
а) acute fever at the onset of the disease (axillary temperature ≥ 38.0°C); b) wet cough; c) physical signs (crepitus/wheezing, bronchial breathing sounds, local dullness to percussion); d) leukocytosis >10×10\^9/L and/or shift of band neutrophils (>10%).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral administration, without food. The tablet should be held in the mouth until complete dissolution. On the first day 8 tablets are administered using the following scheme: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), followed by three more tablets at regular intervals during the rest of the day. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 7 days.
Drug: Raphamin
Oral administration, without food. The tablet should be held in the mouth until complete dissolution. Placebo is administered according to the Raphamin regimen for 7 days.
Drug: Placebo
Tablet for oral use.
Also known as: MMH-407
Tablet for oral use.
Percentage of patients with clinical cure at the test of cure (TOC) visit
Percentage of patients with clinical cure at the TOC visit (on day 8 after randomization based on the physician's assessment of clinical symptoms).
Time frame: On 8 days
Average duration of antibacterial therapy
Average duration of antibacterial therapy in two groups
Time frame: 15 days
Proportions of patients with a positive response to the initial course of antibiotic therapy after 48-72 hours
Proportion of patients with a positive response to the initial course of antibiotic therapy after 48-72 hours in two groups. The main criteria for the effectiveness of the starting regimen of antibacterial therapy after 48-72 hours: a decrease in temperature (below 38.0C), a decrease in the severity of intoxication syndrome and the main clinical symptoms of pneumonia, primarily shortness of breath.
Time frame: 3 days
Proportion of patients who discontinue antibiotic therapy after 7 days of treatment (based on physician assessment of clinical symptoms).
Proportions of patients who discontinue antibiotic therapy after 7 days of treatment in two groups (based on physician assessment of clinical symptoms). Criteria for the sufficiency of antibacterial therapy (all of the following must be present): * persistent decrease in body temperature ≤37.2ºС for at least 48 hours; * absence of intoxication syndrome; * respiratory rate \<20/min (in patients without chronic respiratory failure); * absence of purulent sputum (except for patients with its constant secretion); * the number of leukocytes in the blood \<10×109/l, neutrophils \<80%, young forms \<6%.
Time frame: 7 days
Proportion of patients who required a change in antibiotic 48-72 hours after initiation of therapy.
Proportions of patients who required a change in antibiotic 48-72 hours after initiation of therapy in two groups due to treatment failure. The main criteria for the treatment failure: temperature higher than 38.0C), presence of intoxication syndrome and the main clinical symptoms of pneumonia, shortness of breath.
Time frame: 3 days
Time until a persistent decrease in body temperature ≤37.2ºС (according to the patient's diary).
Time until a persistent decrease in body temperature ≤37.2ºС (according to the patient's diary) in two groups.
Time frame: 15 days
Proportion of patients who required a second course of antibiotic therapy.
Proportions of patients who required a second course of antibiotic therapy in two groups due to treatment failure. The main criteria for the treatment failure: temperature higher than 38.0C), presence of intoxication syndrome and the main clinical symptoms of pneumonia, shortness of breath.
Time frame: 15 days
Proportion of patients who required hospitalization during 15 days of follow-up.
Proportions of patients who required hospitalization during 15 days of follow-up due to treatment failure. The main criteria for the treatment failure: temperature higher than 38.0C), presence of intoxication syndrome and the main clinical symptoms of pneumonia, shortness of breath.
Time frame: 15 days
Number of antipyretic drug doses taken during 7 days of the initial course of antibacterial therapy (per patient).
Average number of antipyretic drug doses taken during 7 days of the initial course of antibacterial therapy (per patient) in two groups according to the patient's diary.
Time frame: 7 days
Proportion of patients without infiltration on x-ray/CT 14 days after randomization.
Proportions of patients without infiltration on X-ray/CT on 14th day after randomization in two groups according to medical records.
Time frame: 14 days
The Presence of Adverse Events (AEs).
The presence and nature of adverse events, their intensity (severity), causal relationship to the study drug, outcome. Based on medical records.
Time frame: 15 days
Changes in Vital Signs (Blood Pressure measured in mm Hg)
Changes in Blood Pressure at the end of treatment. Based on medical records.
Time frame: 15 days
Changes in Vital Signs (Pulse Rate (Heart Rate) measured in beats per minute)
Changes in Heart Rate at the end of treatment. Based on medical records.
Time frame: 15 days
Changes in Vital Signs (Respiratory Rate (Breathing Rate) measured in breaths per minute)
Changes in Respiratory Rate at the end of treatment. Based on medical records.
Time frame: 15 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Mar 2025, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MMH-407
Community-Acquired Pneumonia →